anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:A cosmetic, obtained by incorporating benzoguanamine resin particles containing an ultraviolet light absorber with other components, having improved ultraviolet light absorbing effect, good transparent feeling in application to the skin and high safety for the skin. CONSTITUTION:A cosmetic obtained by incorporating benzoguanamine resin particles (having 0.1-0.5mu, preferably 0.1-0.3mu particle diameter) containing an ultraviolet light absorber, preferably 2,2'-dihydroxy-4,4'-dimethoxybenzophenone or 4-imidazoleacrylic acid, with other components. The cosmetic has improved safety for the skin without direct sticking of the ultraviolet light absorber to the skin. Benzoguanamine resin powder, etc. obtained by reacting 99-65pts.wt. benzoguanamine with 1-35pts.wt. p-toluenesulfonamide and 1.2-3.5mol, based on 1mol total of both, formaldehyde in an aqueous medium, and curing the resultant water-soluble meltable resin while keeping the emulsified state with a protective colloid is used as the benzoguanamine resin powder.
Ringer’s Irrigation, USP exerts a mechanical cleansing action for sterile irrigation of body cavities, tissues or wounds, indwelling urethral catheters and surgical drainage tubes, and for washing, rinsing or soaking surgical dressings, instruments and laboratory specimens. It also serves as a vehicle for drugs used for irrigation or other pharmaceutical preparations.

Ringer’s Irrigation, USP provides an isotonic irrigation with the same ionic constituents as Ringer’s Injection, USP, a modification of Ringer’s solution (also called Ringer’s mixture) originally used only as a topical physiologic salt solution.

Ringer’s Irrigation, USP is considered generally compatible with living tissues and organs.

Calcium Chloride in water dissociates to provide calcium (Ca++) and chloride (Cl−) ions. They are normal constituents of the body fluids and are dependent on various physiologic mechanisms for maintenance of balance between intake and output. Approximately 80% of body calcium is excreted in the feces as insoluble salts; urinary excretion accounts for the remaining 20%.

Potassium chloride in water dissociates to provide potassium (K+) and chloride (Cl−) ions. Potassium is the chief cation of body cells (160 mEq/liter of intracellular water). It is found in low concentration in plasma and extracellular fluids (3.5 to 5.0 mEq/liter in a healthy adult). Potassium plays an important role in electrolyte balance.

Normally about 80 to 90% of the potassium intake is excreted in the urine; the remainder in the stools and to a small extent, in the perspiration. The kidney does not conserve potassium well so that during fasting or in patients on a potassium free diet, potassium loss from the body continues resulting in potassium depletion.

Sodium chloride in water dissociates to provide sodium (Na+) and chloride (Cl−) ions. Sodium (Na+) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Chloride (Cl−) has an integral role in buffering action when oxygen and carbon dioxide exchange occurs in the red blood cells. The distribution and excretion of sodium (Na+) and chloride (Cl−) are largely under the control of the kidney which maintains a balance between intake and output.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).

Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na+) plays a major role in maintaining physiologic equilibrium.
<P>PROBLEM TO BE SOLVED: To provide a means for vaccinating a human neonatal and a neonatal animal against a foreign antigen and an antigen associated with disease of a human and an animal, respectively.  <P>SOLUTION: A virus is used for the production of a medicine for vaccinating or treating a neonatal or prenatal animal, including a human, wherein the virus has capability of infecting a cell of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a modified vaccinia virus Ankara. In particular, vaccination of the neonate is carried out against infections with the virus belonging the same virus group as the virus used for vaccination. Moreover, the vaccination of the neonate is carried out against the antigen selected from a foreign antigen and a tumour antigen, which are different from the antigen associated with the virus. By using the virus, a level of a factor activating a dendritic cell or its precursor cell is increased, the number of the dendritic cell or its precursor cell is increased, and (or) a production amount and (or) a cellular content of an interferon (IFN) or IL-12 are increased.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Provided is an oxygen saturation estimation system using a photoplethysmography (PPG) signal sensing ring. The system includes a server. The server includes a signal quality classification component configured to classify the qualities of a first wavelength PPG signal and a second wavelength PPG signal as good or bad, and an oxygen saturation estimation component configured to estimate oxygen saturation from the first wavelength PPG signal and the second wavelength PPG signal. The PPG signal sensing ring includes a plurality of sensors on different position, wherein each of the plurality of sensors is configured to measure the wavelength PPG signal and the second wavelength PPG signal, and each of the plurality of sensors includes a first wavelength light source, a second wavelength light source, and a photoelectric conversion device. The terminal can include a sensor selection component configured to select a sensor, which having measured a combination of first and second wavelength test PPG signals with the highest signal quality among a plurality of first and second wavelength test PPG signals, from among the plurality of sensors as a sensor for measuring the first and second wavelength PPG signals. Therefore, the present invention is capable of selecting a sensor in accordance with a blood vessel position and shape which can differ depending on users.
Patients with relapsed and refractory myeloma who have a measurable paraprotein in the serum or urine or measurable protein by Freelite or measurable disease by plasmacytoma will be given a combination of bendamustine and bortezomib each cycle. Response rate (PR or better after 2 cycles) and duration of response will be assessed. Therapy will be continued until disease progression. The bendamustine would be used in a day 1, day 4 dosing schedule after each dose of bortezomib to take advantage of the chemosensitizing properties of bortezomib. This minimizes the days of treatment to just the first week and allows rebound of blood counts. This will be a phase II trial with dose reduction as necessary.

Bendamustine is a drug which appears to be non-cross-resistant with other alkylating agents in vitro and in vivo. Thus, we hypothesize that the combination of bortezomib and bendamustine will have activity in relapsed/refractory myeloma.
A double-blind, randomized, placebo-controlled, comparative multicenter study in two groups. A total of 120 patients with uncomplicated influenza or other acute respiratory viral infections are planned to be randomized. Patients will be randomized into 2 groups: 60 patients in the treatment group 200 mg XC221 and 60 patients in the placebo group. The purpose of the clinical trial is to assess the safety, tolerability and efficacy of the drug XC21 in treatment of influenza or other acute respiratory viral infections. The primary objective is to demonstrate the difference between the groups in the time of the onset of sustained improvement in clinical symptoms according to the Modified Jackson Scale. The study will consist of the following periods: screening (duration not more than 36 hours from the moment of the first symptoms of the disease), treatment period (3 days), follow-up period (11 ± 1 days after completion of treatment with the study drug/placebo). The duration of participation in the study for each patient is no more than 16 days and 12 hours.
This invention relates to the use of water-soluble zinc salts as anti-viral agents in condom lubricants. Such zinc-containing anti-viral lubricants can be coated onto condoms during manufacture and enclosed in sealed watertight packages containing the lubricated condoms. Preferred lubricants contain at least one water-soluble lubricating agent, such as glycerin or polyethylene glycol, and a suitable zinc salt, as well as some quantity of water to promote ionization of the salt and release of zinc ions (Zn++). If water is used, such lubricants may also contain a thickening or suspending agent, such as a cellulose derivative, a natural gum compound, or a hydrophilic polymer, to provide a gel; alternately, the carrier may be a different type of water-containing formulation, such as a cream, emulsion, or ointment. Suitable zinc salts include water-soluble organic salts having relatively low molecular weights (including zinc acetate, butyrate, gluconate, glycerate, glycolate, lactate, propionate, etc.). Highly ionizing inorganic salts, such as zinc chloride or sulfate, can also be used in some formulations. Preferred salts are those which cause no detectable irritation. The zinc-containing condom lubricants described herein are intended to reduce the risk of infection by a sexually transmitted pathogen, in a user who may be at risk.
Several biomarkers have been proposed to identify frailty, a multisystemic age-related syndrome. However, the complex pathophysiology and the absence of a consensus on a comprehensive and universal definition make it challenging to pinpoint a singular biomarker or set of biomarkers that conclusively characterize frailty. This review delves into the main laboratory biomarkers, placing special emphasis on those associated with various pathways closely tied to the frailty condition, such as inflammation, oxidative stress, mitochondrial dysfunction, metabolic and endocrine alterations and microRNA. Additionally, we provide a summary of different clinical biomarkers encompassing different tools that have been proposed to assess frailty. We further address various imaging biomarkers such as Dual Energy X-ray Absorptiometry, Bioelectrical Impedance analysis, Computed Tomography and Magnetic Resonance Imaging, Ultrasound and D3 Creatine dilution. Intervention to treat frailty, including non-pharmacological ones, especially those involving physical exercise and nutrition, and pharmacological interventions, that include those targeting specific mechanisms such as myostatin inhibitors, insulin sensitizer metformin and with special relevance for hormonal treatments are mentioned. We further address the levels of different biomarkers in monitoring the potential positive effects of some of these interventions. Despite the availability of numerous biomarkers, their performance and usefulness in the clinical arena are far from being satisfactory. Considering the multicausality of frailty, there is an increasing need to assess the role of sets of biomarkers and the combination between laboratory, clinical and image biomarkers, in terms of sensitivity, specificity and predictive values for the diagnosis and prognosis of the different outcomes of frailty to improve detection and monitoring of older people with frailty or at risk of developing it, being this a need in the everyday clinical practice.
PURPOSE:The titled solution useful as an iron agent for intravenous injection for treating iron-deficiency anemia, etc., having high utility of iron and hardly any side effects, being stabilized with a tricarboxylic acid or its salt. CONSTITUTION:A tricarboxylic acid (e.g., citric acid, isocitric acid, tricarballylic acid, etc.) or its salt (e.g., Na salt, K salt, etc.) is added to a previously prepared iron hydroxide colloidal solution, so that the colloidal solution is stabilized. Properly 5-20mol, preferably 10-15mol tricarballylic acid or its salt is used based on 1gram atom iron in colloidal particles of iron hydroxide colloidal solution to be stabilized. When the solution is used as an iron agent for intravenous injection, preferably it has 7.0-7.5 pH. The iron hydroxide colloidal solution, for example, can be prepared by dropping an aqueous solution of ferric chloride to boiling distilled water.
FIELD: organic chemistry, biochemistry, pharmacy. SUBSTANCE: invention relates to novel derivatives of imidazole of the general formula (I)   where n 1  means a whole number from 1 to 3; A means hydrogen atom, linear or branched C 1 -C 10 -alkyl that can be optionally substituted with C 3 -C 7 - cycloalkyl or lower alkoxy-group, or radical taken among the group indicated in the invention claim; Y means radical taken among the group described in the invention claim, or to its novel pharmaceutically acceptable salts. Compounds show inhibitory activity with respect to activity of farnesyltransferase. Also, invention relates to method of synthesis of these compounds, intermediate compounds and pharmaceutical composition based on new derivatives of imidazole. Invention can be used in medicine for prophylaxis and treatment of cancer. EFFECT: new compounds indicated above, improved method of synthesis, valuable antitumor properties. 12 cl, 7 tbl
Zyprexa is one of the most commonly prescribed second generation antipsychotic drugs (SGAs), but its (and other SGA's) side effects contribute to the development of obesity and to the "Metabolic Syndrome." Both conditions, which are more prevalent even in unmedicated schizophrenic patients, are associated with increased cardiovascular morbidity and mortality. The mechanisms of these side effects are likely to be multifactorial and to involve peripheral and central factors alike. The present proposal asks a fundamental question: How the endogenous opioidergic systems are involved in Zyprexa-induced obesity and in related metabolic disturbances. We further hypothesize that if the excess of central opioid activity creates metabolic problems for patients, it is reasonable to expect amelioration of the symptoms through blockade of opioid receptors. The proposed project is designed to test this hypothesis by complimenting clinical psychopharmacology with pain medicine research and functional magnetic resonance imaging (fMRI) to empirically measure clinical outcomes of Zyprexa pharmacotherapy augmentation with the opioid receptor antagonist, naltrexone. Our objectives and hypotheses are as follows: to determine the effects of naltrexone on weight gain, metabolic (e.g., cholesterol, lipids, insulin, leptin and glucose levels), anthropometric and nutritional characteristics in Zyprexa treated schizophrenic patients, to examine the effects of naltrexone on subjective pain ratings, and to investigate the safety and tolerability of naltrexone in Zyprexa-treated schizophrenic patients.
This study is open-label which means that all subjects will receive the study medication. The medicine-benralizumab-will be given to subjects in addition to the medicines they are already taking to treat their EGPA such as oral steroids (e.g. prednisone) and medicines that reduce the activity of their immune system. Drugs that are sometimes used (i.e., standard of care) to reduce the activity of the immune system in EGPA (in addition to oral steroids) include azathioprine, methotrexate, mycophenolate mofetil and cyclophosphamide. Information about how the stud drug that you get affects the subjects body and their health will be collected through a number of tests, procedures and questions.

The study medicine, benralizumab, will be given to subjects as one injection 30 mg under skin every four weeks for 12 weeks and then every 8 weeks for 16 weeks for a total of 5 treatments. During the treatment phase of this study, a study staff member will call the subjects to see how they are doing, what medications they are taking and if they are able to decrease their steroid use. The study is a total of 9 study visits in a 44 week time period. Everyone who takes part in the study will continue to receive his/her existing treatments for EGPA (although their dose of oral steroids may be reduced during the study.
Synthetic bone models have increasing utility in orthopaedic research due to their low cost and low variability and have been shown to be biomechanically equivalent to human bones in a variety of ways. The rise in additive manufacturing (AM) for orthopaedic applications presents an opportunity to construct synthetic whole-bone models for biomechanical testing applications, but there is a lack of research comparing these AM models to cadaveric or commercially available bone surrogates. This study compares the mechanical properties of 3D printed clavicle models to commercially available (4th generation Sawbones) and human cadaveric clavicles via nondestructive cyclic 4-point bending, axial compression, and torsion, and a final axial compression test to failure. Commercially available synthetic clavicles had 57.8-203% higher superior-inferior bending rigidity (p < 0.0001), 80.9-198% higher axial stiffness (p < 0.001), and 314-557% higher torsional rigidity (p < 0.05) on average than AM and cadaveric clavicles. Cadaveric and AM clavicles printed from a BoneMatrix/VeroWhite composite material had similar failure mechanisms under axial compression while AM VeroWhite clavicles experienced catastrophic failure, but these groups did not have significantly different ultimate failure loads. Together, these results demonstrate that current commercially available synthetic clavicles may be too rigid to emulate the mechanical properties of elderly cadaveric clavicles, and that AM bone models can closely mimic these cadaveric bones in a variety of biomechanical loading schemes. These results show promising applications for future work using 3D printed bone surrogates for biomechanical analysis of orthopaedic implants and other surgical repair techniques.
The invention provides a fodder additive for stomatitis of calves. The additive comprises cortex phellodendri, indigo naturalis, borax, dried alum, borneol and Chinese gall. The raw materials complement one another in function and take effect respectively; the cortex phellodendri clears heat, dries dampness, purges fire for removing toxin, brings down a fever and clears hectic heat; the indigo naturalis has the effect of removing superior-phrenic heat phlegm; the borax has the effect of clearing heat, removing phlegm, removing toxin and resisting septic, and is mainly used for treating swelling and pain of throats and sores of mouths and tongues; the dried alum has astringency, antiphlogosis, antiseptic, hemostasis, parasite killing and itching relieving effects; the borneol induces resuscitation, clears heat, relieves pain, resists septic and relieves itching; the Chinese gall is mainly used for treating deficiency syndrome of the lung, spontaneous perspiration, night sweating, lingering dysentery and chronic diarrhea. The objective of treating the stomatitis of the calves can be achieved through combination of the herbs. The stomatitis of the calves is inflammation of surface and deep tissues of oral mucosas of the calves, and can make sick calves difficult in eating and chewing. In order to treat the stomatitis, the fodder additive is added into fodder for the calves, and the objective of treating the stomatitis of the calves is achieved after the calves eat the fodder.
A system. A system includes a computing system. The computing system includes a processor, a first module, a second module, and a third module. The first module is communicably connected to the processor and is configured for receiving chain of custody information associated with an item. The second module is communicably connected to the processor and is configured for determining a status of the item based on the received chain of custody information. The third module is communicably connected to the processor and is configured for arranging data into a specified format. The data includes the status of the item and the chain of custody information. The third module is also configured for transmitting the data.
In the first interview; patient diagnosis form and Constipation Quality of Life scale will be applied. In order to evaluate the routine bowel habits of the patients, no application will be made in the first week and the patients will be asked to complete the Defecation Diary, Visual Comparison Scale and the Bristol Stool Consistency Scale for 1 week when defecation occurs. Afterwards, the reflexology socks designed by the researcher for the patients; will be told to wear and walk 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday). Patients will be asked to continue the application for 4 weeks. The patients will be administered the Defecation Diary, the Visual Comparison Scale, and the Bristol Stool Consistency Scale when defecation occurs daily during the application. In addition, on the 30th day of the application, the Constipation Quality of Life Scale will be administered to the patients again.
A preparation method of fermented product of medicinal herbs is provided to inhibit oxidation by removing reactive oxygen species, and suppress side effects in the skin application of fermented product of medicinal herbs, so that atopic dermatitis is improved. A preparation method of fermented product of medicinal herbs having improving effects on atopic dermatitis comprises the steps of: extracting medicinal herbs including mulberry tree leaf and skin, Angelica gigas radix leaf, mugwort, Zanthoxylum piperitum fruit and leaf, Portulaca oleracea L., cockscomb, ground cherry, Aconitum carmichaeli Debx, Rhododendron brachycarpum G. Don, Acertegmentosum, viscumalbum var. coloratum, Ambrosia artemisiifolia var. elatior, Phytolacc americana L., Firmiana simplex, bog rhubarb, Confederate rose, Chelidonium majus Linn, Cirsium maackii, Taraxacum platycarpum, Brassica campestris subsp. napus var. nippo-oleifera, Leonurus sibiricus L. and Astragalus sinicus with ethyl alcohol; mixing rice bran with deep seawater, chitosan, oligosaccharide and molasses, culturing the rice bran mixture on soybean paste, and drying the cultured rice bran mixture to prepare rice bran culture medium; suspending the dried rice bran culture medium in solution containing deep seawater, chitosan and oligosaccharide, adding the extracts of medicinal herbs and microorganisms including Bacillus sp., lactic acid bacteria, Actinomycete and yeast into the rice bran suspension, and fermenting the mixture.
Lehfilcon A toric contact lenses worn first, with comfilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) during waking hours for at least 5 days per week, with up to 10-12 hours wear time per day over a 30-day period. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.